Received Jun 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | H3729 | — |
Unstable Boostrix after temperature excursion administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a 30-year-old female patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number H3729 with expiry date 29-AUG-2028) for prophylaxis. On 24-APR-2026, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Unstable Boostrix after temperature excursion administration). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 03-JUN-2026 The temperature excursion was 15.3 degree C as the maximum for 706 hours; no longer stable. This was 1 of the 5 cases, reported by the same reporter.; Sender's Comments: US-GSK-US2026074262:same reporter US-GSK-US2026074328:same reporter US-GSK-US2026074457:same reporter US-GSK-US2026074412:same reporter US-GSK-US2026074411:same reporter